Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedtronicXSWX:MDT 74 3-Year EBITDA Growth Rate is 5.30% as of Apr. 2026, which is 55% below its 10-year median of 11.90. GuruFocus rates XSWX:MDT with a GF Score™ of 74/100 and a GF Value™ of CHF80.28. The stock has 3 warning signs investors should review. Among 692 Medical Devices & Instruments companies, Medtronic ranks worse than 55.2% on this metric.
During the past 12 months, Medtronic's average EBITDA Per Share Growth Rate was 6.60% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 5.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 5.30% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 1.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Medtronic was 26.50% per year. The lowest was -7.10% per year. And the median was 11.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Medtronic 3-Year EBITDA Growth Rate Related Terms
XSWX:MDT vs SYK, BSX, EW: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Medtronic's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medtronic 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medtronic's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Medtronic's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 5.30% mean?
Medtronic (XSWX:MDT) has a 3-Year EBITDA Growth Rate of 5.30% as of Apr. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Medtronic and its competitors. This is 55% below median its historical median of 11.90. According to the industry distribution chart, Medtronic ranks #382 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 55.2%.
Is Medtronic's 3-Year EBITDA Growth Rate too high?
Medtronic's current 3-Year EBITDA Growth Rate of 5.30% is 55% below median its 10-year median of 11.90. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. Medtronic's value of 5.30% is 35.4% below this industry median. Based on the distribution chart, Medtronic ranks #382 out of 692 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Medtronic has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Medtronic's 3-Year EBITDA Growth Rate compare to SYK and BSX?
According to the Medical Devices & Instruments industry distribution chart, Medtronic ranks #382 out of 692 companies for 3-Year EBITDA Growth Rate. This places Medtronic in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.20. Medtronic's value of 5.30% is 35.4% below this benchmark. While the company's 10-year median is 11.90 vs. the industry median of 8.20, Medtronic has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medtronic's current 3-Year EBITDA Growth Rate of 5.30% is 35.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Medtronic and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medtronic's current 3-Year EBITDA Growth Rate is 5.30%, which is 55% below median its own 10-year median of 11.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtronic stock overvalued right now?
Medtronic (XSWX:MDT) has a current 3-Year EBITDA Growth Rate of 5.30%. The stock's GF Value™ is CHF80.28, compared to a current price of CHF69.82 — trading 13% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 5.30%, which is 55% below median its 10-year median of 11.90 and 35.4% below the Medical Devices & Instruments industry median of 8.20. Medtronic's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Medtronic (XSWX:MDT), the current 3-Year EBITDA Growth Rate is 5.30% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medtronic (XSWX:MDT) Overvalued in 2026?
Based on GuruFocus' analysis, Medtronic stock appears to be undervalued.
The current stock price of CHF69.82 is trading 13% below its estimated GF Value™ of CHF80.28.
Key valuation signals for XSWX:MDT:
3-Year EBITDA Growth Rate: 5.30% (55% below median its 10-year median of 11.90)
GF Value™: CHF80.28 vs. price of CHF69.82 (13% below fair value)
Industry Position: 35.4% below the Medical Devices & Instruments median (#382 of 692)
No single metric tells the full story. See the XSWX:MDT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
74GF Score
Get the complete analysis for XSWX:MDT
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MDT has been successfully added to your 
